Kulkarni Ketan P, Marwaha Ram K
*Department of Pediatrics, Division of Pediatric Hematology-Oncology, Stollery Children Hospital, Edmonton, AB, Canada †Division of Pediatric Hematology-Oncology, Advanced Pediatric Center, PGIMER, Chandigarh, India.
J Pediatr Hematol Oncol. 2013 Oct;35(7):573-6. doi: 10.1097/MPH.0b013e31829d46f3.
Acute lymphoblastic leukemia has a wide variety of presentations. There is paucity of any data addressing pancytopenia at presentation in acute lymphoblastic leukemia. In this study we assessed 84 patients with pancytopenia at presentation. They had a significantly lower incidence of bulky disease at presentation. A significantly higher fraction of these patients (n=66, 78.57%) opted for therapy (P=0.005) as compared with the rest. The estimated mean survival in patients presenting with pancytopenia (67.2±17.2 mo) was significantly higher (P=0.031, log-rank test) as compared with that of other patients (47.2±7.4 mo). Pancytopenia was an independent predictor of better survival (P=0.043) in multivariate analysis.
急性淋巴细胞白血病有多种临床表现。目前几乎没有关于急性淋巴细胞白血病初诊时全血细胞减少的数据。在本研究中,我们评估了84例初诊时全血细胞减少的患者。他们初诊时出现大包块疾病的发生率显著较低。与其他患者相比,这些患者中选择接受治疗的比例显著更高(n = 66,78.57%)(P = 0.005)。初诊时全血细胞减少患者的估计平均生存期(67.2±17.2个月)显著高于其他患者(47.2±7.4个月)(P = 0.031,对数秩检验)。在多变量分析中,全血细胞减少是生存期较好的独立预测因素(P = 0.043)。